Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.